博茨瓦纳接受抗逆转录病毒治疗的人类免疫缺陷病毒(HIV)感染者的不良母体结局
该回顾性队列研究在博茨瓦纳玛丽娜公主医院纳入11,754名分娩者,其中2,201人(18.7%)感染HIV,97%在分娩时使用抗逆转录病毒治疗(ART),93.5%使用多替拉韦+替诺福韦酯+拉米夫定。与未感染HIV者相比,HIV感染者的子痫前期风险略降低(调整RR 0.84,95%CI 0.71-0.98),子宫破裂风险增加(调整RR 6.54,95%CI 2.33-18.33),其他不良母体结局无显著差异。
要点
- HIV感染者子痫前期风险略低于未感染者(8.4% vs 8.6%,调整RR 0.84,95%CI 0.71-0.98)。
- HIV感染者子宫破裂风险高于未感染者(0.5% vs 0.1%,调整RR 6.54,95%CI 2.33-18.33),但属罕见。
- 出血、感染、子痫、急性心肺事件、输血、宫缩剂、氨甲环酸、ICU入住、机械通气、升压支持及死亡率均无显著差异。
核心结论
- 在广泛使用整合酶链抑制剂(主要为多替拉韦)的 treat-all 时代,HIV感染与未感染者的不良母体产科结局差异很小, notable 例外包括HIV感染者子痫前期风险略降低、子宫破裂风险增加(尽管罕见)。
研究设计与样本
- 回顾性队列研究,数据来自博茨瓦纳玛丽娜公主医院2021年11月至2023年12月出院时的病历,结局记录于Tsepamo出生结局监测和安全分娩研究。
- 共纳入11,754名参与者,其中2,201人(18.7%)为HIV感染孕妇。
主要发现
- HIV感染者中2,135人(97%)在分娩时使用抗逆转录病毒治疗(ART);在已知ART方案的1,996人中,93.5%使用多替拉韦、替诺福韦酯和拉米夫定。
- 在1,090名已知CD4计数的HIV感染者中,757人(69.4%)CD4>500个/微升,仅42人(3.9%)<200个/微升;在1,524名已知病毒载量的HIV感染者中,1,436人(94.2%)初次检测未检出。
- HIV感染者 vs 未感染者:出血90例(4.1%) vs 370例(3.9%),调整RR 0.93(95%CI 0.73-1.17);感染38例(1.7%) vs 126例(1.3%),调整RR 1.56(95%CI 0.97-2.51);子痫6例(0.3%) vs 28例(0.3%),调整RR 1.12(95%CI 0.50-2.53);急性心肺事件15例(0.7%) vs 43例(0.4%),调整RR 1.22(95%CI 0.65-2.27);死亡率5例(0.2%) vs 11例(0.1%),调整RR 1.44(95%CI 0.46-4.57),均无统计学显著差异。
- HIV感染者 vs 未感染者:子痫前期184例(8.4%) vs 818例(8.6%),调整RR 0.84(95%CI 0.71-0.98);子宫破裂12例(0.5%) vs 8例(0.1%),调整RR 6.54(95%CI 2.33-18.33)。
关键数值与推荐
- HIV感染者 vs 未感染者:输注≥2单位浓缩红细胞33例(36.7%) vs 110例(29.8%),P=0.21;额外宫缩剂48例(53.3%) vs 173例(47.1%),P=0.29;使用氨甲环酸31例(34.4%) vs 106例(29.0%),P=0.31;ICU入住4例(0.2%) vs 10例(0.1%),P=0.31;机械通气3例(0.1%) vs 6例(0.1%),P=0.38;升压支持2例(0.1%) vs 2例(0.0%),P=0.16。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate maternal outcomes in a large cohort with high prevalence of human immunodeficiency virus (HIV) infection in Botswana after implementation of a treat-all policy. METHODS: In this retrospective cohort study, data were collected from the medical record at the time of discharge from November 2021 to December 2023. Outcomes were recorded in the Tsepamo Birth Outcomes Surveillance and Safe Birth studies at Princess Marina Hospital in Botswana. We evaluated maternal mortality and obstetric morbidities by HIV status, including preeclampsia, eclampsia, hemorrhage, infection, and acute pulmonary or cardiac conditions at the time of hospital discharge. RESULTS: We included 11,754 participants; 2,201 (18.7%) were pregnant people with HIV infection. Ninety-seven percent (2,135) were on antiretroviral therapy (ART) at time of delivery; 1,996 (93.5%) of those with a known ART regimen were on dolutegravir, tenofovir disoproxil fumarate, and lamivudine. Of the 1,090 people with HIV infection with known CD4 counts, 757 (69.4%) had more than 500 cells/microliter, and only 42 (3.9%) had fewer than 200 cells/microliter. Of 1,524 people with HIV infection with known viral loads, 1,436 (94.2%) were undetectable on initial testing. There were no statistically significant differences in incidence of hemorrhage (90 [4.1%] vs 370 [3.9%], adjusted risk ratio [RR] 0.93, 95% CI, 0.73-1.17), infection (38 [1.7%] vs 126 [1.3%], adjusted RR 1.56, 95% CI, 0.97-2.51), eclampsia (6 [0.3%] vs 28 [0.3%], adjusted RR 1.12, 95% CI, 0.50-2.53), acute pulmonary or cardiac conditions (15 [0.7%] vs 43 [0.4%], adjusted RR 1.22, 95% CI, 0.65-2.27), transfusion of 2 or more units of packed red blood cells (33 [36.7%] vs 110 [29.8%], P= .21), additional uterotonics (48 [53.3%] vs 173 [47.1%], P= .29), use of tranexamic acid (31 [ 34.4%] vs 106 [29.0%], P= .31), intensive care unit admission (4 [0.2%] vs 10 [0.1%], P= .31), mechanical ventilation (3 [0.1%] vs 6 [0.1%], P= .38), pressor support (2 [0.1%] vs 2 [0.0%], P= .16), or mortality (5 [0.2%] vs 11 [0.1%], adjusted RR 1.44, 95% CI, 0.46-4.57) in people with HIV infection compared with those without HIV infection. There were few notable differences, including a slightly reduced risk of preeclampsia (184 [8.4%] vs 818 [8.6%], adjusted RR 0.84, 95% CI, 0.71-0.98) and, although rare, an increased risk of uterine rupture (12 [0.5%] vs 8 [0.1%], adjusted RR 6.54, 95% CI, 2.33-18.33) in people with HIV infection compared with those without HIV infection. CONCLUSION: There was little difference in adverse maternal obstetric outcomes between people with and those without HIV infection in the treat-all era with integrase strand inhibitors (primarily dolutegravir); notable exceptions included a slightly reduced risk of preeclampsia and, although rare, an increased risk of uterine rupture in those with HIV infection.
引用
- Agudogo JS, Jackson-Gibson M, Macharia A, et al. Adverse Maternal Outcomes Among People With Human Immunodeficiency Virus (HIV) Using Antiretroviral Therapy in Botswana. Obstet Gynecol. 2025. PMID: 40839877. doi:10.1097/AOG.0000000000006039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。